Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference
NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference, taking place February 14 - 18, 2022.
|11th Annual SVB Leerink Global Healthcare Conference|
|Date:||Wednesday, February 16th, 2022|
|Time:||11:20am Eastern Time|
|Webcast:||The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com|
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing batoclimab, formerly referred to as IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Released February 9, 2022